Summit Clinical Trials for Ivonescimab (SMT112)
Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in the U.S. & EU.*
Brings two validated mechanisms in oncology1,2,3 into ONE novel tetravalent molecule.
 |
|
 |
Phase 3 Study: NCT05184712
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment. |
|
Phase 3 Study: NCT05899608
A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer. |
 |
|
 |
For Information on the Ivonescimab MOA
Click here
For additional information on the HARMONi or the HARMONi-3 clinical trials, please visit clinicaltrials.gov or contact medinfo@smmttx.com
1. Manegold et al., (2016); JTO 12:2.194-207.; 2. Pardoll, Drew M. (2012) Nature Reviews Cancer vol. 12,4 :252-64.; 3. Tamura et al., (2020) Med Oncol 37:2, 10.1007.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).
